The Anti Radiation Drugs Market is estimated to be valued at US$ 587.4 million in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Anti radiation drugs help protect cells and tissues from the harmful effects of ionizing radiation. These drugs are used to treat radiation poisoning caused by accidental radiation exposure during medical radiation treatments or nuclear disasters. The major drug classes used as anti radiation drugs include myeloid growth factors, antibodies, cytokines, and stem cell therapies. They work by stimulating production of blood cells and repairing damaged tissues.
Increased demand for protective treatments: With increasing use of medical radiation for diagnosis and cancer treatment as well as growing nuclear energy industry, demand for anti radiation drugs that can help prevent or treat radiation poisoning is growing. This is driving research and development of novel anti radiation drugs.
New product launches: Several pharmaceutical companies are investing in R&D to develop more effective anti radiation drugs. For example, in 2022, RxBio Inc. launched new stem cell therapy drug Rad-C which showed promising results in protecting against radiation poisoning in clinical trials. Such new product launches are expected to boost market growth during forecast period.
The global anti radiation drugs market is segmented based on drug type, application, end user and distribution channel. Based on drug type, the market is segmented into radioprotectors and mitigators. The radioprotectors segment is dominating the market currently as these drugs help in protecting healthy cells and tissues from radiation exposure during radiation therapy or chemotherapy for cancer treatment.
Political: Regulations regarding the clinical trials and approvals of anti radiation drugs are well defined by regulatory bodies like FDA which provide a stable regulatory environment for market growth.
Economic: The rising incidence of cancer cases globally is driving healthcare spending on oncology which is positively impacting the anti radiation drugs market.
Social: Growing social awareness about radiation safety and availability of treatment options for radiation exposure is increasing the adoption of anti radiation drugs.
Technological: Advancements in drug delivery systems and combination therapies are expanding the therapeutic scope of anti radiation drugs, thereby supporting the market growth.
The global Anti Radiation Drugs Market Share is expected to witness high growth, exhibiting a CAGR of 6.8% over the forecast period, due to increasing cancer cases requiring radiation therapy globally.
Regional analysis: The North America region currently dominates the anti radiation drugs market owing to major technological advancements and presence of key market players in the US. However, Asia Pacific region is expected to witness the highest CAGR during the forecast period due to rising healthcare expenditure, increasing cancer prevalence and rising awareness in countries like China and India.
Key players: Key players operating in the anti radiation drugs market are RxBio Inc., Annova Chem Inc., Medicom Healthcare Ltd., Onconova Therapeutics, Genome Protection Inc., Grace Therapeutics LLC, Amgen Inc., Partner Therapeutics Inc., Jubilant Life Sciences Ltd., Cipla Inc., Stium Inc., Soligenix Inc., Aeolus Pharmaceuticals, PharmaIN Corp, Immune Modulators Inc. These key players are focusing on new product launches, collaborations and regulatory approvals to strengthen their market position.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it